AR050451A1 - Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de la hepatitis c - Google Patents

Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de la hepatitis c

Info

Publication number
AR050451A1
AR050451A1 ARP050103317A ARP050103317A AR050451A1 AR 050451 A1 AR050451 A1 AR 050451A1 AR P050103317 A ARP050103317 A AR P050103317A AR P050103317 A ARP050103317 A AR P050103317A AR 050451 A1 AR050451 A1 AR 050451A1
Authority
AR
Argentina
Prior art keywords
virus
hepatitis
pharmaceutical compositions
recombinant
compositions against
Prior art date
Application number
ARP050103317A
Other languages
English (en)
Inventor
Cabrera Santiago Duenas
Aizpurua Ivis Guerra
Rivero Nelson Acosta
Lasa Alexis Musacchio
Ponce De Le Alvarez-Lajonchere
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR050451A1 publication Critical patent/AR050451A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Virus de viruela aviar recombinante para combinaciones proteicas basadas en antígenos del virus de la hepatitis C y su uso en composiciones farmacéuticas capaces de inducir una respuesta inmune celular contra el virus de la hepatitis C, después de la administracion de un numero reducido de dosis. Las composiciones farmacéuticas son utiles para la prevencion y tratamiento de infecciones asociadas con el virus de la hepatitis C en mamíferos. Reivindicacion 1: Un virus de viruela aviar recombinante caracterizado porque contiene fragmentos de ADN derivados del virus de la hepatitis C, en una region no esencial del genoma del VVA, capaz de inducir una respuesta celular específica contra antígenos del VHC.
ARP050103317A 2004-08-11 2005-08-09 Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de la hepatitis c AR050451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040174A CU23470A1 (es) 2004-08-11 2004-08-11 Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c

Publications (1)

Publication Number Publication Date
AR050451A1 true AR050451A1 (es) 2006-10-25

Family

ID=40262893

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103317A AR050451A1 (es) 2004-08-11 2005-08-09 Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de la hepatitis c

Country Status (14)

Country Link
EP (1) EP1787656A1 (es)
JP (1) JP2008508890A (es)
KR (1) KR20070040814A (es)
CN (1) CN101035560A (es)
AR (1) AR050451A1 (es)
AU (1) AU2005270612A1 (es)
BR (1) BRPI0514274A (es)
CA (1) CA2575293A1 (es)
CU (1) CU23470A1 (es)
MX (1) MX2007001749A (es)
MY (1) MY170516A (es)
RU (1) RU2353651C2 (es)
WO (1) WO2006015557A1 (es)
ZA (1) ZA200701079B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
ATE290592T1 (de) * 1993-11-04 2005-03-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
CU22642A1 (es) 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
AU6226100A (en) * 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming

Also Published As

Publication number Publication date
MY170516A (en) 2019-08-08
JP2008508890A (ja) 2008-03-27
CU23470A1 (es) 2009-12-17
EP1787656A1 (en) 2007-05-23
BRPI0514274A (pt) 2008-06-10
MX2007001749A (es) 2007-04-20
WO2006015557A1 (es) 2006-02-16
KR20070040814A (ko) 2007-04-17
CA2575293A1 (en) 2006-02-16
CN101035560A (zh) 2007-09-12
AU2005270612A1 (en) 2006-02-16
RU2353651C2 (ru) 2009-04-27
ZA200701079B (en) 2008-07-30
RU2007108290A (ru) 2008-09-20

Similar Documents

Publication Publication Date Title
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
EP4306538A3 (en) Peptide oligonucleotide conjugates
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
CY1111480T1 (el) Αναστολεις πολυμερασης toy rna που εξαρταται απο to rna του ιου ηπατιτιδας c και συνθεσεις και θεραπευτικες αγωγες χρησιμοποιωντας αυτους
ES2061708T3 (es) Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus.
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
NO20044941L (no) Modifisert vacciniavirus Ankara til vaksinasjon av nyfodte
MY149395A (en) Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus
DK1949913T3 (da) Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин
AR050451A1 (es) Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de la hepatitis c
MX2020012373A (es) Vacuna de peptido inverso.
NO20053189L (no) HVC-kombinasjonsterapi.
WO2005056051A3 (en) Hepatitis b vaccines and compositions
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
DE50304603D1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
CY1107371T1 (el) Αυξηση της θυμοσινης στην γενετικη ανοσοποιηση
ATE476197T1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
WO2020255009A3 (en) Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
WO2006098769A3 (en) Multipathogen and monopathogen protection against the bacterial and viral infections associated with biological warfare, cardiac diseases, and cancers

Legal Events

Date Code Title Description
FB Suspension of granting procedure